Delving into the Latest Updates on Grand Theravac Life Science (Nanjing) Co., Ltd. with Synapse

Overview

Basic Info

Introduction

Founded in 2015 and joining the China Grand Enterprise Group in 2016, Grand Theravac Life Science (Nanjing) Co., Ltd. operates as the vaccine R&D center within the China Grand Pharma Life Science Group. The company is committed to the development of therapeutic vaccines, novel and improved vaccines, and new adjuvant systems, utilizing its core technology platforms in recombinant vaccines based on E. coli and yeast, scale-up fermentation, protein vaccine purification processes, VLP quality assessment, and immunological evaluation.

Tags

Digestive System Disorders

Infectious Diseases

Therapeutic vaccine

Prophylactic vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	2

Top 5 Drug Type	Count

Therapeutic vaccine	1
Prophylactic vaccine	1

Top 5 Target	Count

HBcrAg x L-HBsAg(HBcrAg x L-HBsAg)	1

[Translation] A single-center, randomized, double-blind, controlled design to evaluate the safety and tolerability of recombinant hepatitis B vaccine (Hansenula yeast, CpG and aluminum adjuvant) in healthy people aged 18 years and above with 0, 1, and 6 months immunization schedule. phase I clinical trial

评价不同CpG-QCX1佐剂配比浓度的重组乙型肝炎疫苗以0，1，6月3剂免疫程序接种于18岁及以上人群的安全性和耐受性。探索不同CpG-QCX1佐剂配比浓度的重组乙型肝炎疫苗以0，1，6月3剂免疫程序接种于18岁及以上人群的免疫原性。

[Translation]

To evaluate the safety and tolerability of recombinant hepatitis B vaccines with different concentrations of CpG-QCX1 adjuvant administered to people aged 18 and above using a three-dose immunization schedule of 0, 1, and 6 months. To explore the immunogenicity of recombinant hepatitis B vaccines with different CpG-QCX1 adjuvant concentrations when administered to people aged 18 and above using a three-dose immunization schedule of 0, 1, and 6 months.

Start Date27 Oct 2023

Sponsor / Collaborator

Grand Theravac Life Science (Nanjing) Co., Ltd.

CTR20231429 / RecruitingPhase 2

在经治慢性乙型肝炎患者中评估 TVAX-008 注射液治疗有效性和安全性的多中心、随机、双盲、安慰剂平行对照II 期临床试验

[Translation] A multicenter, randomized, double-blind, placebo-controlled phase II clinical trial evaluating the therapeutic efficacy and safety of TVAX-008 injection in previously treated patients with chronic hepatitis B

主要目的：评价 TVAX-008 注射液治疗核苷（酸）类似物（NAs）经治的慢性乙型肝炎患者的有效性。次要目的：评价 TVAX-008 注射液治疗核苷（酸）类似物（NAs）经治的慢性乙型肝炎患者的安全性。

[Translation]

main purpose: To evaluate the efficacy of TVAX-008 injection in the treatment of nucleoside (acid) analogs (NAs)-treated chronic hepatitis B patients. Secondary purpose: To evaluate the safety of TVAX-008 injection in nucleoside (acid) analogs (NAs)-treated chronic hepatitis B patients.

Start Date30 May 2023

Sponsor / Collaborator

Grand Theravac Life Science (Nanjing) Co., Ltd.

CTR20230989 / RecruitingPhase 1

单中心、随机、盲法、阳性对照设计评价重组乙型肝炎疫苗（TVAX-009B）以0、1、6月程序接种在16岁及以上人群的安全性和免疫原性的I期临床试验

[Translation] A single-center, randomized, blinded, positive-control design phase I clinical trial evaluating the safety and immunogenicity of recombinant hepatitis B vaccine (TVAX-009B) administered in 0, 1, and 6-month schedules in people aged 16 and over

与同类疫苗比较评价重组乙型肝炎疫苗（汉逊酵母）在16岁及以上人群接种的安全性，并探索免疫原性。

[Translation]

To evaluate the safety of the recombinant hepatitis B vaccine (Hansenula spp.) in people aged 16 and above by comparing with similar vaccines, and to explore the immunogenicity.

Start Date29 May 2023

Sponsor / Collaborator

Grand Theravac Life Science (Nanjing) Co., Ltd.

100 Clinical Results associated with Grand Theravac Life Science (Nanjing) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Grand Theravac Life Science (Nanjing) Co., Ltd.

Login to view more data

100 Deals associated with Grand Theravac Life Science (Nanjing) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Grand Theravac Life Science (Nanjing) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 06 Jul 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Approval

2

1

Phase 1 Clinical

Phase 2 Clinical

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

TVAX-008 ( HBcrAg x L-HBsAg )	Hepatitis B, Chronic More	Phase 2
Recombinant Hepatitis B Vaccine(Hansenula polymorpha)(Grand Theravac)	Hepatitis B More	Phase 1
Tetravalent Recombinant Norovirus vaccine(Hansenula Polymorpha)(Grand Theravac Life Science)	Norovirus Infections More	IND Approval
Recombinant Hepatitis B Vaccine (Hansenula polymorpha,CpG and Aluminum Adjuvant)(Grand Theravac Life Science (Nanjing))	Hepatitis B More	IND Approval